Fagron NV (LON:0HNZ)

London flag London · Delayed Price · Currency is GBP · Price in EUR
21.63
-0.38 (-1.70%)
At close: Feb 11, 2026
Market Cap1.50B +29.7%
Revenue (ttm)787.55M +11.9%
Net Income73.45M +9.9%
EPS1.00 +9.6%
Shares Outn/a
PE Ratio20.37
Forward PE16.94
Dividend0.21 (0.93%)
Ex-Dividend DateMay 19, 2025
Volume2,184
Average Volume3,925
Open22.00
Previous Close22.00
Day's Range21.63 - 22.00
52-Week Range18.00 - 23.03
Beta0.30
RSI41.53
Earnings DateFeb 12, 2026

About Fagron NV

Fagron NV, a pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, patients, and worldwide. It operates through three segments: Essentials, Brands, and Compounding Services. The company's products include DiluCap, a line of excipients to compound every capsule formulation; Imuno TF Complex helps in regulation of immune responses; Pigmerise, a natural phytocomplex for hypopigmentation disorders, such as vitiligo; Pentravan uses for avoiding first-pass metabolism and preventing gastrointe... [Read more]

Industry Medical, Dental, and Hospital Equipment and Supplies
Founded 1990
Employees 3,989
Stock Exchange London Stock Exchange
Ticker Symbol 0HNZ
Full Company Profile

Financial Performance

In 2024, Fagron NV's revenue was 871.96 million, an increase of 14.28% compared to the previous year's 762.99 million. Earnings were 80.55 million, an increase of 14.18%.

Financial numbers in EUR Financial Statements